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cally significant (p> .05), a trend toward more days hospitalized from disease-asso-
ciated complications was observed for patients managed with WW (Mean= 9.21, 
respectively) and non-systemic treatment (Mean= 8.27) than patients treated 
with chemotherapy (Mean= 7.25) or TKIs (Mean= 8.22). ConClusions: Among 
patients diagnosed with RRDTC, watch and wait and non-systemic treatment 
options remain common. A large direct cost burden may be observed given the 
frequent and long hospital stays.
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objeCtives: There is increasing pressure on regulators from patients, physicians 
and industry for earlier access to pharmaceuticals for serious diseases. In reaction, 
in March 2014 the European Medicines Agency (EMA) announced it was piloting 
adaptive licensing, and the Medicines and Health care products Regulatory Agency 
(MHRA) unveiled their Early Access to Medicines Scheme. Nevertheless, there are 
questions over how, and if, Phase II trial benefits can be predictive of clinical advan-
tages in Phase III studies, which this research aims to address. Methods: Phase 
III data of any Non-Small Cell Lung Cancer (NSCLC) oncologic appraised by the 
EMA, or that had failed Phase III clinical trials, since 2002 was extracted along with 
its corresponding Phase II data. Statistical tests were conducted using Pearson’s 
coefficient correlation. Results: 12 oncologics were identified with both Phase 
II and III readouts, 6 of which met their Phase III trial primary endpoint. Overall 
Response Rates (ORRs) reported in Phase II trials varied from 0%-61% (mean 24%). 
4/4 (100%) drugs with Phase II ORRs > 30% met their primary endpoint vs. only 
2/8 (25%) with ORRs ≤ 30%. Phase II ORRs were strongly correlated with Phase III 
Progression-Free Survival (PFS) (r2= 0.864, p< 0.0005) and Overall Survival (OS) out-
comes (r2= 0.858, p< 0.001). Nevertheless, 5/6 drugs that failed their Phase III primary 
endpoints had comparative Phase II data indicating benefits versus these same 
comparators, most notably onartuzumab, whose Phase III trial was terminated early 
due to lack of efficacy, despite demonstrating significant OS benefits of 8.8 months 
in Phase II. ConClusions: In NSCLC, Phase II ORRs can be strongly predictive of 
the magnitude of PFS and OS readouts in Phase III trials. However, comparative 
advantages in Phase II trials seem to be poorly predictive of OS benefits in Phase 
III studies, raising questions over the appropriateness of approving drugs on early 
stage comparative data.
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objeCtives: To investigate feasibility and effectiveness of a cervical screening 
program with DNA tests as preliminary assay versus usual cytology protocols in 
Umbria Region. Methods: A large cohort of 35-64 aged women afferent to the 
unique regional laboratory was considered. The usual algorithm with cervical cytol-
ogy as primary test was followed in January 2008–June 2010, whereas in August 
2010–October 2011 high-risk human papillomavirus (HR-HPV) DNA test was used 
as primary screening. The cohorts were compared in terms of acceptance rate of 
invitation, cytological results, molecular results including HPV genotype, detection 
rate of histological lesions. Results: A total of 31,228 women were invited: 21,249 
were suggested to undergo classical cervical cytology screening, 9,979 HR-HPV DNA 
test as primary screening. A similar rate of adhesion (56.6% vs. 56.5%) was observed. 
Age-related differences were evidenced, with younger women (35-49) more prone to 
accept the invitation to HR-HPV DNA testing rather than usual cytology screening 
(61.6% vs. 55.5%; p< 0.0001); analogously, uninvited younger women spontaneously 
requesting cervical screening were more prone to specifically request molecular 
than classical cytological testing (24.8% vs. 10.8%; p< 0.0001). Among the 6,272 
HR-HPV DNA testing women, 396 (6.4%) were positive, and, among them, 141 (36%) 
featured an altered cytology. All patients with altered cytology were suggested to 
undergo colposcopy and 106 out of 141 (75.1%) answered to the invitation. Among 
them, 89 (84%) featured abnormal histology with 48 (45.3%) CIN1 and 41 (38.7%) 
CIN2. If comparing the CIN2 detection rate within the two studied periods, it was 
almost doubled using the HR-HPV DNA than pap test as primary assay (0.64% vs. 
0.37%; p= 0.005). Finally, the implementation of the DNA test screening program did 
not increase total costs. ConClusions: Although with some limits, the introduc-
tion of HR-HPV DNA primary testing resulted feasible and effective, significantly 
increasing detection of severe lesions.
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objeCtives: Prognosis for relapsed or refractory (R/R) MCL patients with existing 
treatments is poor; most patients progress within ~4 months. Ibrutinib, an oral once 
daily Bruton’s tyrosine kinase inhibitor showed durable single agent activity with 
good response rate in 111 R/R MCL patients and a median progression free survival 
(PFS) of 13.9 months. Ibrutinib received breakthrough designation and United States 
Food and Drugs Administration approval for use in MCL patients who received at 
least one prior therapy (R/R MCL). This indirect analysis aims to compare the efficacy 
Systematic searches in the electronic databases MEDLINE, EMBASE and The 
Cochrane library were conducted and 53 online databases (including HTA agency 
websites, international ministries of health, and clinical trials. gov) were hand 
searched for clinical guidelines in the treatment of MO caused by RVO. Results: 
Fifteen documents on treatment pathways or guidance used internationally were 
identified from the hand searches. No papers or abstracts were found from the 
electronic database searches. There were considerable between-jurisdiction dif-
ferences in the guidance for the management of MO caused by RVO. These differ-
ences were consolidated to produce two amalgamated treatment pathways. In 
total, eight treatment positions for interventions in the treatment of RVO subtypes 
were identified. For one of the identified positions – treatment of ischaemic branch 
RVO – no licensed treatment currently exists. ConClusions: The described sys-
tematic methodology for the construction of treatment pathways may be used 
by manufacturers in early drug development decisions to identify unmet clini-
cal needs, understand which treatment positioning may provide the most value, 
and identify future treatment comparators in the same indication. Guidelines 
to inform such commercial strategies may not be identifiable from electronic 
database searches alone with extensive hand searches being a necessity. Between 
jurisdiction guideline nuances also need to be taken into account when consider-
ing the target market for an intervention in development.
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objeCtives: Ophthalmology pharmaceutical market is growing worldwide due 
to rising aging population, new delivery technologies and changing lifestyle. 
However, challenges like patent expiry of major brands and lack of awareness 
still persists. Therefore, it is important to be aware of the upcoming treatment 
options, changing patients’ needs and requirement of cost effective therapies. 
This analysis provides an overview of the recent trends and future scenario in 
Ophthalmology market. Methods: Pharmaceutical companies sponsored clinical 
trials initiated from January 2011 to April 2014 in Glaucoma, Age-related Macular 
Degeneration (AMD), Diabetic Retinopathy (DR) / Diabetic Macular Edema (DME), 
Dry eye syndrome (DES) and Retinal vein occlusion (RVO) have been considered. 
Only Phase I - III trials listed on public registries have been considered. Results: 
The data showed that > 30% of the trials are being conducted on Glaucoma in 
USA, Europe, Asia and Australia. This is followed by AMD (24%), DR/DME (21%), 
DES (17%) and RVO (7%). Also, > 50% ophthalmological trials are being conducted 
in USA; followed by Europe (~25%) and Asia (~20%). In Europe, 71 trials have been 
conducted on 48 molecules, of which 69% are chemical entities, 19% are biologicals 
and > 10% are entities like RNAi (oligonucleotide, aptamers), DARPin. Eye drops 
(46%) and intravitreal injections (37%) are the key topical and parenteral formula-
tions, respectively. 10% of the trials have been conducted on oral formulations. In 
Europe, EU5 countries comprise of 43% of the trials and Germany has maximum 37 
trials. Novartis has conducted trials in maximum 30 countries, followed by Santen 
(19), Pfizer (15) and Allergan (13) in Europe. ConClusions: Based on the analysis, 
currently, Glaucoma, AMD and DR/DME are the major focus of the companies in 
ophthalmology. Though, biologicals and RNAi are being tested routinely, chemical 
entities are foremost modalities. Similarly, eye drops remain as preferred method 
of delivery with respect to other newer delivery techniques.
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objeCtives: Most patients with differentiated thyroid cancer (DTC) have an 
excellent prognosis after receiving standard treatment, consisting of surgery and 
often adjuvant radioactive iodine (RAI). However, a subgroup of patients prove to 
have progressive DTC which is refractory to RAI (RRDTC). Treatment options for 
RRDTC are limited. This study investigated the treatment patterns and health care 
resource utilization of patients with RRDTC. Methods: Data were collected by 
performing a retrospective chart review study in the US and 5EU (France, Germany, 
Italy, Spain, UK) with physicians recruited from an online panel. Physicians pro-
vided clinical information on 1 to 4 of their RRDTC patients in an online survey. 
Demographics, disease history, treatment information, and health care resource 
were included and reported descriptively. Health care resource use was compared 
across treatment classes using general linear models. Results: 231 physicians 
participated and provided a total of 700 patient charts (44.1% of charts were from 
the US and 11-12% from each 5EU country). 45.0% of patients were male with a 
mean age at diagnosis of 55.1 years [SD= 12.4]. 52.0% of patients were treated 
with systemic treatment (e.g., 16.9% tyrosine kinase inhibitors [TKIs] only; 13.3% 
chemotherapy only). The remaining 48.0% were either in a watch and wait (“WW”) 
period (20.1%) or were managed with non-systemic palliative therapies (27.9%; eg, 
external beam radiation). Overall, patients averaged 15.87 days hospitalized per 
year (due to disease related complications or side effects). Although not statisti-
